NRX Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

NRX Pharmaceuticals

12/08/2023 03:05

* NRX Pharmaceuticals Inc  NRXP.OQ   NRXP.O  is expected
to report
results on August 14.
    * 
    * ​Refinitiv's mean analyst estimate for NRX Pharmaceuticals
Inc
is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NRX
Pharmaceuticals Inc is $5​, above​ its last closing price
of $0.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.14       -0.14      -0.16     Missed  -14.3
 Dec. 31 2023              -0.14      -0.16     Missed  -10.3
 Sep. 30 2022  -0.14       -0.14      -0.14     Met     0​
 Jun. 30 2022  -0.10       -0.10      -0.11     Missed  -10
 ​​                                                     
                                                        ​
 This summary was machine generated August 12 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated